SlideShare a Scribd company logo
PH in the Real World
Case Studies
Terry Fortin MD
Duke Pulmonary Vascular Disease Center
November 4, 2022
• Mean PAP > 20 mmHg
1
• Wedge < 15 mmHg
2
• PVR > 3 WU (or less)
3
Definition of PAH Clinical, Hemodynamic
6th World Symposium 2018
6th World Symposium on PH 2018
Groups of PH (Framework)
 1. Pulmonary Arterial Hypertension (PAH)
 2. PH owing to left heart disease
 3. PH owing to lung diseases and/or
hypoxia
 4. Chronic thromboembolic pulmonary
hypertension (CTEPH)
 5. PH with unclear multifactorial mechanisms
 (ESRD, Cancer, Hemoglobinopathy, Sarcoid…
Real World : PH or PAH ?
54 yo sickle cell/thallasemia Hgb 7-8
Rheumatoid arthritis SLE overlap/MCTD
CKD on hemodialysis (high output)
History Mitral Valve replacement for remote
endocarditis
Morbid obesity, (BMI>50) OSA on CPAP
LV EF is 45%, HTN, DM, TIA, CAD
Pulmonary embolus x 2 but VQ neg
PFDs with moderate restrictive/ obstructive
lung disease.
Later develops cirrhosis
WCM How did we get from A
to B. What if B came first?
 RH Cath 4/22
 RA 22
 RV 110/20
 PA 104/45 mean 68
 PCWP 28
 Output 7 L/min
 Index 3.2
 PVR 5.7 WU
 ABG 7.25/90/107
 Hgb 17.9
 RH Cath 7/22
 RA 8
 RV 50/10
 PA 52/29 mean 34
 Wedge 14
 output 5.2 L/min
 Index 2.5
 PVR 3.9
WCM 4/2022
 65 yo presents to OSH with “COPD flare and NSTEMI”
 EMS called nonresponsive, 02 sat 60% Placed on BiPAP
 History COPD since 2017, Flare 1-2 times per year . Not on 02
 At OSH ABG 7.1/88/124 on 02
 Elevated troponins, LFTs, AKI, pBNP 1700, Hgb 18
 CT ruled out PE, No pneumonia
 History of sleep apnea x years but never used machine
 On inhalers for COPD No PFDs
 On transfer hypercarbic and hypoxic respiratory failure.
 Diuresis, on /off bipap, ABX and Steroids
WCM
WCM Right and Left Heart Cath 4/2022
Off BIPAP on FI02 30%
 RA 22
 RV 110/20
 PA 104/45 mean 68
 PCWP 28
 AO 129/80 mean 96
 CO 7 L/min CI 3.2
 PVR 5.7 WU No Step up to suggest Shunt
 7.25/90/107 Hgb 17.9 Sat 95%
 Placed back on BIPAP post case
 Two vessel CAD TIMI 3 Flow 80% mid LCx,
 Tandom 80% RCA proximal and mid lesions
 Negative volume about 3 liters+ by this time
Pulmonary Vascular Resistance (PVR) increases
with
hypoxemia,
acidosis,
hypercarbia,
increased catacholamines or sympathetic tone
Illness , inflammation,
Thrombosis
 Very high or low lung volumes increase PVR
Activation of neurohormones negatively impacts
function of RV as well
Relevant principles
Treatment???
 Diuresis
 Give pulmonary vasodilator (inhaled prostacyclin)
 1 and then 2
 Diuresis, initiate CPAP/BIPAP/Trilogy
 IV Prostacyclin
 Dual oral therapy with endothelin antagonist and PDE 5
inhibitor
 Repeat Cath before Discharge?
 More Work up
 CT with No PE, ANA normal, HIV normal, Some ongoing
work up for liver disease
 Had stents to his RCA and LCx
My Plan
 Diuresis
 Sent home with Trilogy Machine
 02 for exertion Per PT assessment
 Shock Liver resolved. AKI resolved
 VBG before Discharge 7.43 pC02 48 post using trilogy in
hospital
 Follow up with Pulmonologist / Sleep
 Seen back in my clinic in 10 Days
 Decreased diuretic, pBNP much improved
 Feeling best he has been in years
 Plan for repeat Right heart cath after on his Sleep machine
for 2 to 3 months as long as he is well
WCM 1st clinic visit
 PFDs Group 3 Disease
 FVC 3.33 L 76%
 FEV1 1.28 L 38%
 FEV1/FVC 38
 FEF25-7% 14%
 TLC 110%
 RV 178%
 DLCO 13.72 52%
 Walk is 393 meters (76% predicated)room air
WCM RH Cath 7/2022
 RA 8, PA 52/29 mean 34, Wedge 14
 Cardiac output is 5.2L/min with index of 2.4
 PVR is 3.9 WU, SVR 13 with mean BP of 78
 TPG 20, DPG 15
 pBNP is 148 ( down from 1700)
 Previous cath pre trilogy and diuresis
 RA 22, Mean PAP 68, wedge 28 (group 2)
 Passive or Post Capillary pressures cause congestion of
venous bed and passive PH
 Increased PA pressure with high wedge normal PVR
 Can then have reversible vasoconsttriction
 TPG < 12 and /or DPD or DPG <7
Reactive or precapillary PH physiologic/anatomic remodeling of
arterioles to compensate or protect upstream pulmonary
venous changes
 PVR>3, TPG >12, DPD or DPG >7
 Early may be reversible and more Chronic irreversible
 Combined pre and post capillary PH
Group 2 Pulmonary HTN
WCM Sep 2022
 Normalization of p BNP pBNP 143 ( < 225 normal)
 ANA negative, Alpha -1 Antitrypsin normal
 Negative VQ
 Bicarb decreased from 35 to 27
 Work up for Liver Disease /Steatohepatitis
 Completed cardiopulmonary Rehab
 No Hospitalizations or COPD flares since 4/22
 Compliant with CPAP
 Set up for echo next visit
WCM
 What Group At least Group 2 and 3 ?1
 Pre and post capillary PH Initially more Pre
 TPG 68-28 =44
 DPG 45-24 = 11
 But high wedge 28
 Does it matter that his pH was 7.25, and pC02 90?
 Group 3
 Sleep issues
 COPD ( Would this be different if ILD)
 VQ was low probability
Patients do NOT always follow the
rules
 Cpc PH Combined Pre and post capillary PH
 Group 3 and Group 2 risk factors/ disease
 IS PAH really PAH?
 Relative Severity of each component or factor
 Would we think about this differently if the lung
disease was ILD and not COPD.
 If the 2nd cath was first cath
 If initial wedge was 20 and not 30
Does the Data Make Sense
and is Data accurate
 Timing of the data
 During hospitalization with some concomitant illness
 Rapid diuresis and wedge pressure looks OK
 Initial CXR suggests otherwise
 Re equilibrate
 Inconsistencies of data
 Echo looks bad Cardiac output is good
 CT or other testing suggest other disease process

More Related Content

Similar to PH in the Real World - Case Studies

Prone ventilation
Prone ventilationProne ventilation
Prone ventilation
RamanGhimire3
 
Catheterisation study and operability assessment
Catheterisation study and operability assessmentCatheterisation study and operability assessment
Catheterisation study and operability assessment
India CTVS
 
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.Bassel Ericsoussi, MD
 
COPD Exacerbations: Significance, Assessment, and Current Management
COPD Exacerbations:Significance, Assessment, and Current ManagementCOPD Exacerbations:Significance, Assessment, and Current Management
COPD Exacerbations: Significance, Assessment, and Current Management
Dr.Mahmoud Abbas
 
Case acute myocarditis
Case acute myocarditisCase acute myocarditis
Case acute myocarditis
Kuan Yu Chiang
 
Portopulmonary Hypertension
Portopulmonary HypertensionPortopulmonary Hypertension
Portopulmonary Hypertension
Sarfraz Saleemi
 
Ventilator Management In Different Disease Entities
Ventilator Management In Different Disease EntitiesVentilator Management In Different Disease Entities
Ventilator Management In Different Disease EntitiesDang Thanh Tuan
 
10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...
10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...
10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...
magdyelmasry3
 
Pulmonary Hypertension for general physicians
Pulmonary Hypertension for general physicians Pulmonary Hypertension for general physicians
Pulmonary Hypertension for general physicians
Sarfraz Saleemi
 
Pphn ppp latest 2
Pphn ppp latest 2Pphn ppp latest 2
Pphn ppp latest 2
chittibabu sontenam
 
PULMONARY EMBOLISM.pptx
PULMONARY EMBOLISM.pptxPULMONARY EMBOLISM.pptx
PULMONARY EMBOLISM.pptx
Gurudaspundpal
 
Drugs for CTEPH - studi farmacologici
Drugs for CTEPH - studi farmacologiciDrugs for CTEPH - studi farmacologici
Drugs for CTEPH - studi farmacologici
CTEPH
 
Current diagnosis and management of PAH from cardiologist point of view
Current diagnosis and management of PAH from cardiologist point of viewCurrent diagnosis and management of PAH from cardiologist point of view
Current diagnosis and management of PAH from cardiologist point of view
財團法人風濕病基金會台灣抗風濕病聯盟
 
Mechanical ventilation scenarios
Mechanical ventilation scenariosMechanical ventilation scenarios
Mechanical ventilation scenarios
Leslie Hernandez
 
Pulmonary arterial hypertension
Pulmonary arterial hypertensionPulmonary arterial hypertension
Pulmonary arterial hypertension
Dr. Taraknath Chatterjee
 
Pulmonary Embolism
Pulmonary Embolism	Pulmonary Embolism
Pulmonary Embolism Khalid
 
Management of persistent hypoxemic respiratory failure in the icu garpestad
Management of persistent hypoxemic respiratory failure in the icu   garpestadManagement of persistent hypoxemic respiratory failure in the icu   garpestad
Management of persistent hypoxemic respiratory failure in the icu garpestadDang Thanh Tuan
 

Similar to PH in the Real World - Case Studies (20)

Unusual Cause of Pulmonary Hypertension
Unusual Cause of Pulmonary HypertensionUnusual Cause of Pulmonary Hypertension
Unusual Cause of Pulmonary Hypertension
 
Prone ventilation
Prone ventilationProne ventilation
Prone ventilation
 
Catheterisation study and operability assessment
Catheterisation study and operability assessmentCatheterisation study and operability assessment
Catheterisation study and operability assessment
 
A Case of Antiphospholipid Antibody Syndrome
A Case of Antiphospholipid Antibody SyndromeA Case of Antiphospholipid Antibody Syndrome
A Case of Antiphospholipid Antibody Syndrome
 
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
Pulmonary Hypertension, Current Guidelines and Future Directions of Therapy.
 
COPD Exacerbations: Significance, Assessment, and Current Management
COPD Exacerbations:Significance, Assessment, and Current ManagementCOPD Exacerbations:Significance, Assessment, and Current Management
COPD Exacerbations: Significance, Assessment, and Current Management
 
Case acute myocarditis
Case acute myocarditisCase acute myocarditis
Case acute myocarditis
 
Portopulmonary Hypertension
Portopulmonary HypertensionPortopulmonary Hypertension
Portopulmonary Hypertension
 
Ventilator Management In Different Disease Entities
Ventilator Management In Different Disease EntitiesVentilator Management In Different Disease Entities
Ventilator Management In Different Disease Entities
 
10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...
10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...
10 Take-home messages of the 2022 ESC/ERS Guidelines for the diagnosis and ...
 
Pulmonary Hypertension for general physicians
Pulmonary Hypertension for general physicians Pulmonary Hypertension for general physicians
Pulmonary Hypertension for general physicians
 
Pphn ppp latest 2
Pphn ppp latest 2Pphn ppp latest 2
Pphn ppp latest 2
 
PULMONARY EMBOLISM.pptx
PULMONARY EMBOLISM.pptxPULMONARY EMBOLISM.pptx
PULMONARY EMBOLISM.pptx
 
Drugs for CTEPH - studi farmacologici
Drugs for CTEPH - studi farmacologiciDrugs for CTEPH - studi farmacologici
Drugs for CTEPH - studi farmacologici
 
Current diagnosis and management of PAH from cardiologist point of view
Current diagnosis and management of PAH from cardiologist point of viewCurrent diagnosis and management of PAH from cardiologist point of view
Current diagnosis and management of PAH from cardiologist point of view
 
Mechanical ventilation scenarios
Mechanical ventilation scenariosMechanical ventilation scenarios
Mechanical ventilation scenarios
 
Pulmonary arterial hypertension
Pulmonary arterial hypertensionPulmonary arterial hypertension
Pulmonary arterial hypertension
 
Pulmonary Embolism
Pulmonary Embolism	Pulmonary Embolism
Pulmonary Embolism
 
Management of persistent hypoxemic respiratory failure in the icu garpestad
Management of persistent hypoxemic respiratory failure in the icu   garpestadManagement of persistent hypoxemic respiratory failure in the icu   garpestad
Management of persistent hypoxemic respiratory failure in the icu garpestad
 
Case 2: Pulmonary Thromboembolism
Case 2: Pulmonary ThromboembolismCase 2: Pulmonary Thromboembolism
Case 2: Pulmonary Thromboembolism
 

More from Duke Heart

From LVAD to Transplant: State of the Art of Advanced Heart Failure Management
From LVAD to Transplant: State of the Art of Advanced Heart Failure ManagementFrom LVAD to Transplant: State of the Art of Advanced Heart Failure Management
From LVAD to Transplant: State of the Art of Advanced Heart Failure Management
Duke Heart
 
When Everything Fails - Advanced Heart Failure: When to Refer?
When Everything Fails - Advanced Heart Failure: When to Refer?When Everything Fails - Advanced Heart Failure: When to Refer?
When Everything Fails - Advanced Heart Failure: When to Refer?
Duke Heart
 
Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?
Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?
Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?
Duke Heart
 
Obesity Management in Heart Failure: Best Practices to Date
Obesity Management in Heart Failure: Best Practices to DateObesity Management in Heart Failure: Best Practices to Date
Obesity Management in Heart Failure: Best Practices to Date
Duke Heart
 
Cardiometabolic Revolution: Comprehensive Metabolic Care in Heart Failure
Cardiometabolic Revolution: Comprehensive Metabolic Care in Heart FailureCardiometabolic Revolution: Comprehensive Metabolic Care in Heart Failure
Cardiometabolic Revolution: Comprehensive Metabolic Care in Heart Failure
Duke Heart
 
Remote Monitoring: Tracking Congestion & Beyond
Remote Monitoring: Tracking Congestion & BeyondRemote Monitoring: Tracking Congestion & Beyond
Remote Monitoring: Tracking Congestion & Beyond
Duke Heart
 
Congestion Matters! How to Assess It: Old and New Methods
Congestion Matters! How to Assess It: Old and New MethodsCongestion Matters! How to Assess It: Old and New Methods
Congestion Matters! How to Assess It: Old and New Methods
Duke Heart
 
Percutaneous Valve Therapies in Heart Failure
Percutaneous Valve Therapies in Heart FailurePercutaneous Valve Therapies in Heart Failure
Percutaneous Valve Therapies in Heart Failure
Duke Heart
 
Devices in the Management of Chronic Heart Failure
Devices in the Management of Chronic Heart FailureDevices in the Management of Chronic Heart Failure
Devices in the Management of Chronic Heart Failure
Duke Heart
 
Mechanical Circulatory Support Devices in the Management of Cardiogenic Shock
Mechanical Circulatory Support Devices in the Management of Cardiogenic ShockMechanical Circulatory Support Devices in the Management of Cardiogenic Shock
Mechanical Circulatory Support Devices in the Management of Cardiogenic Shock
Duke Heart
 
Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...
Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...
Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...
Duke Heart
 
Multidisciplinary Strategies for Improved Care Coordination in Heart Failure
Multidisciplinary Strategies for Improved Care Coordination in Heart FailureMultidisciplinary Strategies for Improved Care Coordination in Heart Failure
Multidisciplinary Strategies for Improved Care Coordination in Heart Failure
Duke Heart
 
Duke HF - Heart Failure Transitional Care
Duke HF - Heart Failure Transitional CareDuke HF - Heart Failure Transitional Care
Duke HF - Heart Failure Transitional Care
Duke Heart
 
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Duke Heart
 
Cardiac Amyloidosis: Diagnostic & Therapeutic Approaches
Cardiac Amyloidosis: Diagnostic & Therapeutic ApproachesCardiac Amyloidosis: Diagnostic & Therapeutic Approaches
Cardiac Amyloidosis: Diagnostic & Therapeutic Approaches
Duke Heart
 
Biomarkers in Ambulatory HF: What to Test and How Often?
Biomarkers in Ambulatory HF: What to Test and How Often?Biomarkers in Ambulatory HF: What to Test and How Often?
Biomarkers in Ambulatory HF: What to Test and How Often?
Duke Heart
 
Functional testing in ambulatory heart failure: What to test and how often?
Functional testing in ambulatory heart failure: What to test and how often?Functional testing in ambulatory heart failure: What to test and how often?
Functional testing in ambulatory heart failure: What to test and how often?
Duke Heart
 
Treatment for HFpEF-Current State of the Art and Ongoing Trials
Treatment for HFpEF-Current State of the Art and Ongoing TrialsTreatment for HFpEF-Current State of the Art and Ongoing Trials
Treatment for HFpEF-Current State of the Art and Ongoing Trials
Duke Heart
 
Heart Failure with Preserved Ejection Fraction: Diagnostic Updates
Heart Failure with Preserved Ejection Fraction: Diagnostic UpdatesHeart Failure with Preserved Ejection Fraction: Diagnostic Updates
Heart Failure with Preserved Ejection Fraction: Diagnostic Updates
Duke Heart
 
Contemporary Principles for the Management of Heart Failure
Contemporary Principles for the Management of Heart FailureContemporary Principles for the Management of Heart Failure
Contemporary Principles for the Management of Heart Failure
Duke Heart
 

More from Duke Heart (20)

From LVAD to Transplant: State of the Art of Advanced Heart Failure Management
From LVAD to Transplant: State of the Art of Advanced Heart Failure ManagementFrom LVAD to Transplant: State of the Art of Advanced Heart Failure Management
From LVAD to Transplant: State of the Art of Advanced Heart Failure Management
 
When Everything Fails - Advanced Heart Failure: When to Refer?
When Everything Fails - Advanced Heart Failure: When to Refer?When Everything Fails - Advanced Heart Failure: When to Refer?
When Everything Fails - Advanced Heart Failure: When to Refer?
 
Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?
Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?
Navigating Worsening HF Events: What is Worsening HF and How to Recognize It?
 
Obesity Management in Heart Failure: Best Practices to Date
Obesity Management in Heart Failure: Best Practices to DateObesity Management in Heart Failure: Best Practices to Date
Obesity Management in Heart Failure: Best Practices to Date
 
Cardiometabolic Revolution: Comprehensive Metabolic Care in Heart Failure
Cardiometabolic Revolution: Comprehensive Metabolic Care in Heart FailureCardiometabolic Revolution: Comprehensive Metabolic Care in Heart Failure
Cardiometabolic Revolution: Comprehensive Metabolic Care in Heart Failure
 
Remote Monitoring: Tracking Congestion & Beyond
Remote Monitoring: Tracking Congestion & BeyondRemote Monitoring: Tracking Congestion & Beyond
Remote Monitoring: Tracking Congestion & Beyond
 
Congestion Matters! How to Assess It: Old and New Methods
Congestion Matters! How to Assess It: Old and New MethodsCongestion Matters! How to Assess It: Old and New Methods
Congestion Matters! How to Assess It: Old and New Methods
 
Percutaneous Valve Therapies in Heart Failure
Percutaneous Valve Therapies in Heart FailurePercutaneous Valve Therapies in Heart Failure
Percutaneous Valve Therapies in Heart Failure
 
Devices in the Management of Chronic Heart Failure
Devices in the Management of Chronic Heart FailureDevices in the Management of Chronic Heart Failure
Devices in the Management of Chronic Heart Failure
 
Mechanical Circulatory Support Devices in the Management of Cardiogenic Shock
Mechanical Circulatory Support Devices in the Management of Cardiogenic ShockMechanical Circulatory Support Devices in the Management of Cardiogenic Shock
Mechanical Circulatory Support Devices in the Management of Cardiogenic Shock
 
Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...
Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...
Opening Doors to Better Care: Initiating and Sustaining Open Access & Medicat...
 
Multidisciplinary Strategies for Improved Care Coordination in Heart Failure
Multidisciplinary Strategies for Improved Care Coordination in Heart FailureMultidisciplinary Strategies for Improved Care Coordination in Heart Failure
Multidisciplinary Strategies for Improved Care Coordination in Heart Failure
 
Duke HF - Heart Failure Transitional Care
Duke HF - Heart Failure Transitional CareDuke HF - Heart Failure Transitional Care
Duke HF - Heart Failure Transitional Care
 
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
 
Cardiac Amyloidosis: Diagnostic & Therapeutic Approaches
Cardiac Amyloidosis: Diagnostic & Therapeutic ApproachesCardiac Amyloidosis: Diagnostic & Therapeutic Approaches
Cardiac Amyloidosis: Diagnostic & Therapeutic Approaches
 
Biomarkers in Ambulatory HF: What to Test and How Often?
Biomarkers in Ambulatory HF: What to Test and How Often?Biomarkers in Ambulatory HF: What to Test and How Often?
Biomarkers in Ambulatory HF: What to Test and How Often?
 
Functional testing in ambulatory heart failure: What to test and how often?
Functional testing in ambulatory heart failure: What to test and how often?Functional testing in ambulatory heart failure: What to test and how often?
Functional testing in ambulatory heart failure: What to test and how often?
 
Treatment for HFpEF-Current State of the Art and Ongoing Trials
Treatment for HFpEF-Current State of the Art and Ongoing TrialsTreatment for HFpEF-Current State of the Art and Ongoing Trials
Treatment for HFpEF-Current State of the Art and Ongoing Trials
 
Heart Failure with Preserved Ejection Fraction: Diagnostic Updates
Heart Failure with Preserved Ejection Fraction: Diagnostic UpdatesHeart Failure with Preserved Ejection Fraction: Diagnostic Updates
Heart Failure with Preserved Ejection Fraction: Diagnostic Updates
 
Contemporary Principles for the Management of Heart Failure
Contemporary Principles for the Management of Heart FailureContemporary Principles for the Management of Heart Failure
Contemporary Principles for the Management of Heart Failure
 

Recently uploaded

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 

Recently uploaded (20)

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 

PH in the Real World - Case Studies

  • 1. PH in the Real World Case Studies Terry Fortin MD Duke Pulmonary Vascular Disease Center November 4, 2022
  • 2. • Mean PAP > 20 mmHg 1 • Wedge < 15 mmHg 2 • PVR > 3 WU (or less) 3 Definition of PAH Clinical, Hemodynamic 6th World Symposium 2018 6th World Symposium on PH 2018
  • 3. Groups of PH (Framework)  1. Pulmonary Arterial Hypertension (PAH)  2. PH owing to left heart disease  3. PH owing to lung diseases and/or hypoxia  4. Chronic thromboembolic pulmonary hypertension (CTEPH)  5. PH with unclear multifactorial mechanisms  (ESRD, Cancer, Hemoglobinopathy, Sarcoid…
  • 4. Real World : PH or PAH ? 54 yo sickle cell/thallasemia Hgb 7-8 Rheumatoid arthritis SLE overlap/MCTD CKD on hemodialysis (high output) History Mitral Valve replacement for remote endocarditis Morbid obesity, (BMI>50) OSA on CPAP LV EF is 45%, HTN, DM, TIA, CAD Pulmonary embolus x 2 but VQ neg PFDs with moderate restrictive/ obstructive lung disease. Later develops cirrhosis
  • 5. WCM How did we get from A to B. What if B came first?  RH Cath 4/22  RA 22  RV 110/20  PA 104/45 mean 68  PCWP 28  Output 7 L/min  Index 3.2  PVR 5.7 WU  ABG 7.25/90/107  Hgb 17.9  RH Cath 7/22  RA 8  RV 50/10  PA 52/29 mean 34  Wedge 14  output 5.2 L/min  Index 2.5  PVR 3.9
  • 6. WCM 4/2022  65 yo presents to OSH with “COPD flare and NSTEMI”  EMS called nonresponsive, 02 sat 60% Placed on BiPAP  History COPD since 2017, Flare 1-2 times per year . Not on 02  At OSH ABG 7.1/88/124 on 02  Elevated troponins, LFTs, AKI, pBNP 1700, Hgb 18  CT ruled out PE, No pneumonia  History of sleep apnea x years but never used machine  On inhalers for COPD No PFDs  On transfer hypercarbic and hypoxic respiratory failure.  Diuresis, on /off bipap, ABX and Steroids
  • 7. WCM
  • 8.
  • 9.
  • 10.
  • 11. WCM Right and Left Heart Cath 4/2022 Off BIPAP on FI02 30%  RA 22  RV 110/20  PA 104/45 mean 68  PCWP 28  AO 129/80 mean 96  CO 7 L/min CI 3.2  PVR 5.7 WU No Step up to suggest Shunt  7.25/90/107 Hgb 17.9 Sat 95%  Placed back on BIPAP post case  Two vessel CAD TIMI 3 Flow 80% mid LCx,  Tandom 80% RCA proximal and mid lesions  Negative volume about 3 liters+ by this time
  • 12. Pulmonary Vascular Resistance (PVR) increases with hypoxemia, acidosis, hypercarbia, increased catacholamines or sympathetic tone Illness , inflammation, Thrombosis  Very high or low lung volumes increase PVR Activation of neurohormones negatively impacts function of RV as well Relevant principles
  • 13. Treatment???  Diuresis  Give pulmonary vasodilator (inhaled prostacyclin)  1 and then 2  Diuresis, initiate CPAP/BIPAP/Trilogy  IV Prostacyclin  Dual oral therapy with endothelin antagonist and PDE 5 inhibitor  Repeat Cath before Discharge?  More Work up  CT with No PE, ANA normal, HIV normal, Some ongoing work up for liver disease  Had stents to his RCA and LCx
  • 14. My Plan  Diuresis  Sent home with Trilogy Machine  02 for exertion Per PT assessment  Shock Liver resolved. AKI resolved  VBG before Discharge 7.43 pC02 48 post using trilogy in hospital  Follow up with Pulmonologist / Sleep  Seen back in my clinic in 10 Days  Decreased diuretic, pBNP much improved  Feeling best he has been in years  Plan for repeat Right heart cath after on his Sleep machine for 2 to 3 months as long as he is well
  • 15. WCM 1st clinic visit  PFDs Group 3 Disease  FVC 3.33 L 76%  FEV1 1.28 L 38%  FEV1/FVC 38  FEF25-7% 14%  TLC 110%  RV 178%  DLCO 13.72 52%  Walk is 393 meters (76% predicated)room air
  • 16. WCM RH Cath 7/2022  RA 8, PA 52/29 mean 34, Wedge 14  Cardiac output is 5.2L/min with index of 2.4  PVR is 3.9 WU, SVR 13 with mean BP of 78  TPG 20, DPG 15  pBNP is 148 ( down from 1700)  Previous cath pre trilogy and diuresis  RA 22, Mean PAP 68, wedge 28 (group 2)
  • 17.  Passive or Post Capillary pressures cause congestion of venous bed and passive PH  Increased PA pressure with high wedge normal PVR  Can then have reversible vasoconsttriction  TPG < 12 and /or DPD or DPG <7 Reactive or precapillary PH physiologic/anatomic remodeling of arterioles to compensate or protect upstream pulmonary venous changes  PVR>3, TPG >12, DPD or DPG >7  Early may be reversible and more Chronic irreversible  Combined pre and post capillary PH Group 2 Pulmonary HTN
  • 18. WCM Sep 2022  Normalization of p BNP pBNP 143 ( < 225 normal)  ANA negative, Alpha -1 Antitrypsin normal  Negative VQ  Bicarb decreased from 35 to 27  Work up for Liver Disease /Steatohepatitis  Completed cardiopulmonary Rehab  No Hospitalizations or COPD flares since 4/22  Compliant with CPAP  Set up for echo next visit
  • 19. WCM  What Group At least Group 2 and 3 ?1  Pre and post capillary PH Initially more Pre  TPG 68-28 =44  DPG 45-24 = 11  But high wedge 28  Does it matter that his pH was 7.25, and pC02 90?  Group 3  Sleep issues  COPD ( Would this be different if ILD)  VQ was low probability
  • 20. Patients do NOT always follow the rules  Cpc PH Combined Pre and post capillary PH  Group 3 and Group 2 risk factors/ disease  IS PAH really PAH?  Relative Severity of each component or factor  Would we think about this differently if the lung disease was ILD and not COPD.  If the 2nd cath was first cath  If initial wedge was 20 and not 30
  • 21. Does the Data Make Sense and is Data accurate  Timing of the data  During hospitalization with some concomitant illness  Rapid diuresis and wedge pressure looks OK  Initial CXR suggests otherwise  Re equilibrate  Inconsistencies of data  Echo looks bad Cardiac output is good  CT or other testing suggest other disease process